These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 18348306)

  • 1. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
    Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
    Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization.
    Oikawa M; Yoshiura K; Kondo H; Miura S; Nagayasu T; Nakashima M
    Radiat Oncol; 2011 Dec; 6():168. PubMed ID: 22152285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic instability in the epidermis induced by atomic bomb (A-bomb) radiation: a long-lasting health effect in A-bomb survivors.
    Naruke Y; Nakashima M; Suzuki K; Kondo H; Hayashi T; Soda M; Sekine I
    Cancer; 2009 Aug; 115(16):3782-90. PubMed ID: 19517458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.
    Park K; Kwak K; Kim J; Lim S; Han S
    Hum Pathol; 2005 Jun; 36(6):634-9. PubMed ID: 16021569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for primary breast cancer in Japan: 8-year follow-up of atomic bomb survivors.
    Goodman MT; Cologne JB; Moriwaki H; Vaeth M; Mabuchi K
    Prev Med; 1997; 26(1):144-53. PubMed ID: 9010910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
    Rummukainen JK; Salminen T; Lundin J; Kytölä S; Joensuu H; Isola JJ
    Mod Pathol; 2001 Oct; 14(10):1030-5. PubMed ID: 11598174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
    Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
    Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Male breast cancer incidence among atomic bomb survivors.
    Ron E; Ikeda T; Preston DL; Tokuoka S
    J Natl Cancer Inst; 2005 Apr; 97(8):603-5. PubMed ID: 15840883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of lung tumour mortality risk in the Japanese A-bomb survivors and in the Colorado Plateau uranium miners: support for the ICRP lung model.
    Little MP
    Int J Radiat Biol; 2002 Mar; 78(3):145-63. PubMed ID: 11869470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
    Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer and non-cancer effects in Japanese atomic bomb survivors.
    Little MP
    J Radiol Prot; 2009 Jun; 29(2A):A43-59. PubMed ID: 19454804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of non-cancer diseases in atomic bomb survivors.
    Kodama K; Fujiwara S; Yamada M; Kasagi F; Shimizu Y; Shigematsu I
    World Health Stat Q; 1996; 49(1):7-16. PubMed ID: 8896251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-myc amplifications in primary breast carcinomas and their local recurrences.
    Aulmann S; Adler N; Rom J; Helmchen B; Schirmacher P; Sinn HP
    J Clin Pathol; 2006 Apr; 59(4):424-8. PubMed ID: 16497871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of HER2 is a marker for global genomic instability.
    Ellsworth RE; Ellsworth DL; Patney HL; Deyarmin B; Love B; Hooke JA; Shriver CD
    BMC Cancer; 2008 Oct; 8():297. PubMed ID: 18854030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer among atomic bomb survivors--the relationship of prognosis to pathologic findings.
    Tokunaga M
    Acta Pathol Jpn; 1979 Mar; 29(2):197-209. PubMed ID: 552793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
    Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
    Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study.
    Howe GR; McLaughlin J
    Radiat Res; 1996 Jun; 145(6):694-707. PubMed ID: 8643829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.